JP2021523208A5 - - Google Patents

Info

Publication number
JP2021523208A5
JP2021523208A5 JP2020564227A JP2020564227A JP2021523208A5 JP 2021523208 A5 JP2021523208 A5 JP 2021523208A5 JP 2020564227 A JP2020564227 A JP 2020564227A JP 2020564227 A JP2020564227 A JP 2020564227A JP 2021523208 A5 JP2021523208 A5 JP 2021523208A5
Authority
JP
Japan
Prior art keywords
compound
item
succinate
approximately
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032002 external-priority patent/WO2019222093A1/en
Publication of JP2021523208A publication Critical patent/JP2021523208A/ja
Publication of JP2021523208A5 publication Critical patent/JP2021523208A5/ja
Priority to JP2024031206A priority Critical patent/JP2024051160A/ja
Pending legal-status Critical Current

Links

JP2020564227A 2018-05-14 2019-05-13 ピリミジン誘導体の医薬塩及び障害の処置方法 Pending JP2021523208A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024031206A JP2024051160A (ja) 2018-05-14 2024-03-01 ピリミジン誘導体の医薬塩及び障害の処置方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862671182P 2018-05-14 2018-05-14
US201862671166P 2018-05-14 2018-05-14
US62/671,182 2018-05-14
US62/671,166 2018-05-14
PCT/US2019/032002 WO2019222093A1 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024031206A Division JP2024051160A (ja) 2018-05-14 2024-03-01 ピリミジン誘導体の医薬塩及び障害の処置方法

Publications (2)

Publication Number Publication Date
JP2021523208A JP2021523208A (ja) 2021-09-02
JP2021523208A5 true JP2021523208A5 (cg-RX-API-DMAC7.html) 2022-05-20

Family

ID=68540756

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564227A Pending JP2021523208A (ja) 2018-05-14 2019-05-13 ピリミジン誘導体の医薬塩及び障害の処置方法
JP2024031206A Pending JP2024051160A (ja) 2018-05-14 2024-03-01 ピリミジン誘導体の医薬塩及び障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024031206A Pending JP2024051160A (ja) 2018-05-14 2024-03-01 ピリミジン誘導体の医薬塩及び障害の処置方法

Country Status (11)

Country Link
US (1) US12084431B2 (cg-RX-API-DMAC7.html)
EP (2) EP4234547A3 (cg-RX-API-DMAC7.html)
JP (2) JP2021523208A (cg-RX-API-DMAC7.html)
KR (1) KR20200144579A (cg-RX-API-DMAC7.html)
CN (1) CN112313223A (cg-RX-API-DMAC7.html)
AU (1) AU2019269372A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020023107A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099737A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020012063A (cg-RX-API-DMAC7.html)
TW (1) TWI831780B (cg-RX-API-DMAC7.html)
WO (1) WO2019222093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
CA3138648A1 (en) * 2019-05-22 2020-11-26 Shanghai Hansoh Biomedical Co., Ltd. Indole derivative-containing inhibitor, preparation method therefor and application thereof
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023277172A1 (en) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Process for preparing pharmaceutical salts of pyrimidine derivatives
WO2023283206A1 (en) * 2021-07-07 2023-01-12 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof
WO2023011505A1 (zh) * 2021-08-06 2023-02-09 上海和誉生物医药科技有限公司 嘧啶或吡啶衍生物及其制备方法和在药学上的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1024544C (zh) 1986-03-31 1994-05-18 联合碳化农产化学品公司 协同的植物生长调节剂组合物
WO1987005898A2 (en) 1986-03-31 1987-10-08 Rhone-Poulenc Nederlands B.V. Use of malonic acid derivative compounds for retarding plant growth
AU7284387A (en) 1986-03-31 1987-10-20 Union Carbide Agricultural Products Company Inc. Use of malonic acid derivative compounds for increasing crop yield
AU5391099A (en) 1998-07-30 2000-02-21 American Home Products Corporation Substituted quinazoline derivatives
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
AU2003237790A1 (en) 2002-05-14 2003-12-02 Baylor College Of Medicine Small molecule inhibitors of her2 expression
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP1778648A2 (en) 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
RU2008119994A (ru) 2005-10-21 2009-12-10 Мерк энд Ко., Инк. (US) Ингибиторы калиевых каналов
CA2629249C (en) 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
TW200826843A (en) 2006-09-13 2008-07-01 Sumitomo Chemical Co Thiadiazole compound and use thereof
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
EP2396004A4 (en) 2009-02-11 2012-07-25 Reaction Biology Corp SELECTIVE KINASE HEMMER
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
CA2760778A1 (en) 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ,エルエルシー 融合二環キナーゼ阻害剤
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
EP2852585A1 (en) 2012-05-11 2015-04-01 AbbVie Inc. Nampt inhibitors
US20130303509A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
RU2650512C2 (ru) 2013-09-18 2018-04-16 Бейджин Ханми Фармасьютикал Ко., Лтд. Соединение, ингибирующее активности киназ ВТК и/или JAK3
WO2015039613A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2015140717A1 (en) 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CA2949793C (en) * 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
CN106995437A (zh) * 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
KR102502992B1 (ko) * 2016-09-12 2023-02-24 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제

Similar Documents

Publication Publication Date Title
CA3160899C (en) Spiro compound serving as erk inhibitor, and application thereof
EP4282416A2 (en) Process of manufacture of a compound for inhibiting the activity of shp2
JP7841008B2 (ja) セピアプテリンの薬学的に許容される塩
ES2290281T5 (es) Sal de succinato de O-desmetil-venlafaxina
JP2023062189A (ja) 癌を処置する方法
CA2981746C (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
CN119060066A (zh) 取代的芳基或杂芳基并双环类抑制剂及其制备方法和应用
JP6479970B2 (ja) ウラシル化合物の新規結晶
KR20080044841A (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
BR112015017963A2 (pt) composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
CN105849108A (zh) 磷脂酰肌醇3-激酶抑制剂的制备方法
BR112019020840A2 (pt) sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos
JP7659343B2 (ja) ピロロピリミジン系化合物の塩、その結晶及びその使用
BR112020023107A2 (pt) sais farmacêuticos de derivados de pirimidina e método de tratamento de distúrbios
CN112142679A (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
MX2013010702A (es) Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen.
BR112017024785B1 (pt) Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3- il]-2-etil-6-metilfenoxi}-propano-1,2-diol, composição farmacêutica, e, uso
CN114736214B (zh) 一种倍半萜衍生物、其药物组合物及其制备方法和用途
US12252469B2 (en) Crystalline forms of (E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide
AU2024271907A1 (en) Hdac1/2 selective inhibitor and use thereof
JPS58208275A (ja) 5−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
RU2020140818A (ru) Фармацевтические соли производных пиримидина и способ лечения заболеваний
CN104650109A (zh) 紫杉烷类化合物
CN108864114B (zh) 选择性a2a受体拮抗剂
AU2009321384A1 (en) Polymorphs